AZD7442 - a new monoclonal antibody administer... - CLL Support
AZD7442 - a new monoclonal antibody administered by intramuscular injection is a potential game changer for CLL patients at risk of COVID-19
You need to be a member of this community to see this post.
Read more about...
6 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
STORM CHASER MISSES THE TARGET
Following hard on the heels of Regeneron, who just posted lukewarm results from the RECOVERY trial...
Breaking News! The AZD7442 PROVENT Phase III Prophylaxis Trial met its primary endpoint in preventing symptomatic COVID-19!
Clinical Trial Breaking News Today! CLL Society is delighted to share today's readout from the...
Clinical Trials of Monoclonal antibodies AZD7442 against SARS=CoV-2 (COVID19) - majority of sites in UK and USA
There are two clinical trials of monoclonal antibodies that target covid19.
AstraZeneca is...
Calling UK CLLers - Is government about to abandon support for protective monoclonal antibodies?
There is ample evidence now that many CLL patients don't respond well to vaccination against the...
UK first to trial AstraZeneca 'antibody cocktail' aimed at non-vaccine patients
I'm not recruiting for Astrazeneca, but news broke this morning that they are to start phase 3...
Related Posts
Development of AstraZeneca's SARS-CoV2 spike monoclonal antibodies (AZD7442)
Living in the USA with CLL and want to know where to sign up for your COVID-19 Vaccination? A State-by-State List- Ronapreve approved for CEV patients in UK
- The failing effectiveness of COVID-19 monoclonal antibodies against BA.1, BA.4-5, BA.4.6, BA.2.75, BJ.1 and BQ.1.1
Important SARS-CoV-2 and Covid-19 information for Chronic Lymphocytic Leukaemia/CLL patients
